Get the Stockscreener App
4.17
3.73%
0.15
Pre-market:
4.20
0.03
+0.72%
Agenus Inc stock is traded at $4.17, with a volume of 862.31K.
It is up +3.73% in the last 24 hours and up +25.23% over the past month.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
See More
Previous Close:
$4.02
Open:
$4.06
24h Volume:
862.31K
Relative Volume:
1.23
Market Cap:
$173.22M
Revenue:
$114.20M
Net Income/Loss:
$-3.08M
P/E Ratio:
-10.73
EPS:
-0.3885
Net Cash Flow:
$-77.20M
1W Performance:
+7.20%
1M Performance:
+25.23%
6M Performance:
+13.01%
1Y Performance:
+34.95%
1-Day Range:
$4.05
$4.27
1-Week Range:
$3.64
$4.27
52-Week Range:
$2.71
$7.34
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
4.17 | 173.22M | 114.20M | -3.08M | -77.20M | -0.3885 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Agenus (AGEN) officer Garo Armen takes May 2026 salary in stock - Stock Titan
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update - Business Wire
Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo Finance
AGEN SEC FilingsAgenus 10-K, 10-Q, 8-K Forms - Stock Titan
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - TMX Newsfile
AGEN News | AGENUS INC (NASDAQ:AGEN) - ChartMill
[ARS] AGENUS INC SEC Filing - Stock Titan
Agenus (NASDAQ: AGEN) proxy outlines equity pool increase and option exchange - Stock Titan
AGENUS EV-to-OCF: -2.51 | Fairly Valued - GuruFocus
MSN Money - MSN
Agenus (NASDAQ:AGEN) Shares Cross Above 200 Day Moving AverageHere's Why - MarketBeat
Director Susan B. Hirsch receives 105,000 Agenus (NASDAQ: AGEN) stock options - Stock Titan
Equity grants: Agenus (AGEN) awards 305,000 stock options to director-officer Buell - Stock Titan
[Form 4] AGENUS INC Insider Trading Activity - Stock Titan
Director Timothy Wright receives 105K AGEN (NASDAQ: AGEN) stock options grant - Stock Titan
Agenus (NASDAQ: AGEN) accounting chief awarded stock options in lieu of cash bonus - Stock Titan
Stock options granted to Agenus (AGEN) director and officer Armen Garo - Stock Titan
Agenus (AGEN) director Brian Corvese granted 210,000 stock options - Stock Titan
Agenus (AGEN) price target increased by 48.39% to 23.46 - MSN
AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer - BioSpace
Agenus to Host First 2026 Stakeholder Webcast - The National Law Review
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs - 투데이안
Here's Why Agenus (AGEN) is a Strong Momentum Stock - Yahoo Finance
Agenus Q4 2025 earnings preview - MSN
AGEN (Agenus Inc.) Q4 2025 loss far narrower than expected, shares rise 3.23 percent in today’s session.Community Trade Ideas - Xã Thanh Hà
Agenus presents four abstracts on cancer therapies at ASCO By Investing.com - Investing.com India
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 - BioSpace
Agenus designa a BAP Pharma como socio global exclusivo para BOT+BAL - The Joplin Globe
Agenus (NASDAQ: AGEN) director Armen receives 3,403 fully vested shares as salary - Stock Titan
Promising Phase I Results for BOT/BAL and agenT-797 in PD-1 Refractory Gastroesophageal Cancer - Oncodaily
Agenus presents four abstracts on cancer therapies at ASCO - Investing.com
Agenus Inc. (NASDAQ:AGEN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Agenus enters global partnership with BAP Pharma for investigational BOT+BAL access - Traders Union
Agenus (NASDAQ: AGEN) asks shareholders to approve 5M shares, highlights BOT+BAL data - Stock Titan
Agenus cancer cocktail records 0% response rate, missing midstage goal - BioSpace
Is Agenus (AGEN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Agenus (AGEN) presents new phase 1b clinical data on BOT/BAL combination for MSS mCRC - MSN
Agenus reports trial data for cancer drug combination therapy By Investing.com - Investing.com Australia
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer - Lelezard
Agenus (AGEN) Presents Promising Trial Results for Advanced Canc - GuruFocus
Agenus Reports Phase II Data Demonstrating Immune Reprogramming a - The National Law Review
Agenus reports trial data for cancer drug combination therapy - Investing.com
Agenus cancer drug combo kept 43% alive at 18 months in study - Stock Titan
Has Agenus (AGEN) Outpaced Other Medical Stocks This Year? - Eastern Progress
Can Agenus (AGEN) Run Higher on Rising Earnings Estimates? - Eastern Progress
April 2026 Overview Highlights BOT+BAL Progress in MSS Colorectal Cancer – Agenus - Oncodaily
Agenus unveils 2026 catalyst roadmap with focus on BOT plus BAL and BATTMAN expansion - Traders Union
Agenus : Corporate Overview - marketscreener.com
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):